Business Description
Enveric Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US29405E4061
Total Employee Number:
6Description
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 78.1 | |||||
3-Year EPS without NRI Growth Rate | 75.1 | |||||
3-Year FCF Growth Rate | 77.8 | |||||
3-Year Book Growth Rate | -85.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.58 | |||||
9-Day RSI | 37.61 | |||||
14-Day RSI | 35 | |||||
3-1 Month Momentum % | 19.89 | |||||
6-1 Month Momentum % | -45.74 | |||||
12-1 Month Momentum % | -85.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.66 | |||||
Quick Ratio | 11.66 | |||||
Cash Ratio | 10.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -345.6 | |||||
Shareholder Yield % | -70.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -218.64 | |||||
ROA % | -173.94 | |||||
ROIC % | -4053.25 | |||||
3-Year ROIIC % | -347.79 | |||||
ROC (Joel Greenblatt) % | -4155.71 | |||||
ROCE % | -218.66 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | -0.09 | |||||
EV-to-EBITDA | -0.09 | |||||
EV-to-FCF | -0.09 | |||||
| Price-to-Net-Current-Asset-Value | 0.54 | |||||
| Price-to-Net-Cash | 0.59 | |||||
Earnings Yield (Greenblatt) % | -1111.11 | |||||
FCF Yield % | -142.02 |
GF Value™
Enveric Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enveric Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 46 days | ||
| General meeting for 2026 | 2026-05-28 10:00 | 2.14 (-4.04%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.29 (-5.37%) | ||
| Needham’s Virtual Psychedelics Forum | 2026-04-27 13:00 | 5.04 (+23.23%) | ||
| Annual report for 2025 | 2026-03-27 | 1.86 (-3.63%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 1.86 (-3.63%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 5.46 (-7.30%) | ||
| 0.0833333:1 Stock Split | 2025-10-28 | 7.38 (+0.90%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 07:00 | 10.92 (-8.50%) |
Show
Entries
Guru Commentaries on NAS:ENVB
No articles.
Press Release
Articles on Enveric Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers